Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Marie-Christin HoffmannGiulio CavalliNatalie FadleEleonora CantoniEvi RegitzOctavian FleserPhilipp KlemmMarina ZaksElisabeth StögerCorrado CampochiaroAlessandro TomelleriElena BaldisseraJörg Thomas BittenbringVincent ZimmerJochen PfeiferYvan FischerKlaus-Dieter PreussMoritz BewarderBernhard ThurnerSabrina FuehnerDirk FoellLorenzo DagnaChristoph KesselLorenz ThurnerPublished in: Journal of clinical immunology (2024)
Autoantibodies neutralizing IL-1Ra may represent a novel patho-mechanism in a subgroup of Still's disease patients, which is sensitive to high-dose IL-1 blocking therapy.
Keyphrases
- high dose
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- systemic lupus erythematosus
- prognostic factors
- clinical trial
- stem cells
- ankylosing spondylitis
- patient reported outcomes
- chronic kidney disease
- mesenchymal stem cells
- cancer therapy
- drug delivery
- interstitial lung disease
- cell therapy
- replacement therapy